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Erythropoietic protoporphyria is an inherited disorder caused 
by deficient activity of the enzyme ferrochelatase . We have 
examined the ferrochelatase gene in an II-year-old female 
with protoporphyria and have found that she is heterozygous 
for a mutation at a conserved residue in the exon 3 donor 
splice site consensus sequence (T(+ 2)-+G). This is inherited 
from her father, who also has deficient ferrochelatase act iv-
E rythropoietic protoporphyria (EPP) is an inherited dis-ease caused by deficient activity of the enzyme ferroche-latase (heme synthase) [1]. Accumulation of protopor-phyrin causes photosensitivity [2] and occasionally fatal liver failure [3]. Fluorescence of protoporphyrin-laden 
red cells (fluorocytes) under long-wavelength ultraviolet (UV) 
light is characteristic of the condition [4]. Although EPP is regarded 
as an autosomal dominant disorder, parent-to-offspring transmis-
sion of disease occurs in less than 10% of cases [5] and enzymatic 
studies in affected families suggest that there are several patterns of 
inheritance [6]. Recessive transmission of disease has now been con-
firmed in a severely affected patient who has been found to be a 
compound heterozygote for two missense mutations affecting the 
mature ferrochelatase enzyme [7]. 
Our group [8] and Nakahashi et af [9] have cloned the human 
ferrochelatase gene and independently localized it to chromosome 
18q22. The gene contains 11 exons and spans about 45 kilo base 
pairs (kb) of genomic DNA [10] . Thus far, molecular investigation 
of ferrochelatase cDNA in patients with protoporphyria has re-
vealed three missense mutations [7,11], and putative splicing abnor-
malities of exons 2 [1 2], 9 [13], and 10 [14]. However, a defect in a 
splice site consensus sequence has been demonstrated in only one 
case involving a splicing anomaly [13]. 
The aim of our study was to understand the molecular basis of this 
disease as a first step towards the provision of genetic counseling for 
affected families. We have investigated a family affected by proto-
porphyria by studying abnormalities of porphyrin metabolism and 
by molecular analysis of the ferrochelatase gene. We report here a 
mutation of a highly conserved base at the exon 3 donor site in the 
ferrochelatase gene. This causes defective splicing of the primary 
transcript, leading to the enzyme deficiency in members of this 
family. The presence of this mutation alone, however, is not suffi-
cient to explain the occurrence of symptomatic disease. 
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ity. As a consequence of the mutation, ferrochelatase tran-
scripts are aberrantly spliced and give rise to mRNA mole-
cules in which sequences corresponding to exon 3 are absent. 
This leads to the expression of a ferrochelatase protein lack-
ing a central region of 40 amino acids. Key words: donor site/ 
mutation/exo ll 3/inheritance. ] Invest Dermato/ 102:481- 484, 
1994 
MATERIALS AND METHODS 
Subjects The p~oband was a 9-year-old girl who had suffered from pain, 
erythema, and skm swellmg followmg sun exposure since early infancy. 
Physical examination showed mild scarring on her forearms and face. Both 
parents were healthy. Apart from the proposita, there was no history of 
photosensitivity in other family members. 
Biochemical Studies Peripheral blood films were examined for fluoro-
cytes under ultraviolet A illumination (4). Red-cell protoporphyrin concen-
trations were determined by the method of Piomelli (15). Ferrochelatase 
enzyme function was determined as zinc chelatase activity in peripheral 
blood mononuclear cells, an accurate measure of ferrochelatase activity 
[6,16]. The incorporation of zinc (zinc acetate, Sigma Chemical Co., St. 
Louis, MO) into protoporphyrin IX (Porphyrin Products, Logan, UT) was 
followed by fluorimetry in a sonicated lysate of mononuclear cells prepared 
from 10 1111 of penpheral blood [16]. The reference range was determined in 
36 healthy control subjects and expressed as 95% confidence limits of the 
mean value (±2 SO). 
Genomic Southern Blotting Genomic DNA was extracted from 10 ml 
of peripheral blood (17) and digested with the restriction endonucleases 
BeaRI and Pst! enzymes (New England Biolabs). After electrophoresis in a 
0.8% agarose gel, the DNA was transferred to a nylon filter (Hybond-N, 
Amersham) and probed with a radio labeled full-length ferrochclatase cDNA 
probe (18). 
Ferrochelatase cDNA Studies Ferrochelatase mRNA was analyzed in 
freshly isolated peripheral blood mononuclear cells, and in cultured lym-
phocytes after stimulation by a mitogen. Mononuclear cel ls extracted from 
1? ml of peripheral blood were either snap-frozen in liquid nitrogen imme-
diately, or after 4 d growth in culture medium containing 1 Jig/ml of phyto-
hemagglutinin (Sigma). Total cellular RNA was extracted by the method.of 
ChomczYI~ski and Sacchi (19) and reverse-transcribed using random hex-
an:er pnmmg [18] (Murine Moloney Leukaemia Virus reverse transcriptase, 
Glbco BRL). Ferrochclatase cDNA was amplified from total cellular cDNA 
by means of the polymerase chain reaction (PCR) (20) (DNA thennal cycler, 
Perkin Elmer Cetus) with primers derived from the published cDNA 
sequence (9) to generate a 1328-base pair (bp) product. The primers con-
tained 5' BeaRI restriction si tes (underlined) to faci litate cloning: 
primer A,CGGAA TTCAA TGCGTTCACTCGGCGCAAAC; primer 
B,CGGAATTCTTGGGCATTTGCCTAACGCCAC. The products and 
a plasmid vector (pBluescript II SK M13(+) plasmid vector, Stratagene) 
were digested with BeaR!, ligated together, and cloned into NM522 bacte-
rial strain 4 (Stratagene) [18J. Recombinant clones were identified by hy-
bridization to radio labeled ferrochelatase cDNA and sequenced by the di-
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Table I. Biochemical Investigation of the Patient and her Family 
Patient 
Father 
Mother 
Red-Cell 
Protoporphyrin 
Fluorocytes' (,ug/dl)' 
+++ 
++ 
825.0 
65.5 
52.8 
• Reference range: 0-64.5 tLg/dl. 
b Reference range: 3.0-9.0. 
Zinc Chelatase Activity 
(nmol Zn Protoporphyrin/mg 
Protein/h)b 
0.7 
2.9 
3.5 
' Fluorocytes: -, none seen; +, < 1/ 10,000 red cells; ++, 1-5/10,000 red cells; 
+++, > 5/10,000 red cells. 
deoxynucleotide procedure [21] using T7 DNA polymerase (SEQUENASE 
version 2.0, United States Biochemical) . 
Genomic DNA Studies Genomic DNA was extracted from 10 ml of 
peripheral blood [17] and a 315-bp sequence containing exon 3 and flankin g 
sections of introns 2 and 3 amplified using the PCR. Primers were based on 
the genomic ferrochelatase sequence determined from a AEMBL3 clone. 
They contained additional non-complementary EeoRI or HilldIII restriction 
sites to fac ilitate cloning (as shown in lower case): primer 1,CGgaattc 
AGTGCCAAGGTTATAATCGAGG (EcoRI); primer 2,GCaagctt CA-
GATGTCCCCGAATAGGTATC (Hit/dIll). Amplified products and M13 
bacteriophage vectors (mp18 and 19, Gibco BRL) were digested with 
EcoRI and Hit/dIll enzymes and then ligated together. Recombinant clones 
(NM522 strain 4, Stratagene) were identified by plaque hybridization to a 
radiolabeled ferrochelatase genomic probe [18] and sequenced by the di-
deoxynucleotide procedure as described above. 
RESULTS 
Biochemical Investigation The propos ita had a profound defi-
ciency of heme synthase, her activity being 11.7% of the mean 
control value. Although her father was not photosensitive, he also 
had ferrochelatase deficiency with fluorocytes and a raised red-cell 
protoporphyrin concentration (see Table I). The mother showed no 
biochemical abnormalities although her enzyme activity was only 
58.3% of the mean control value. This is near the lower 95% confi-
dence limit of th e normal range, and is in fact lower than in any of 
the 36 healthy control subjects. 
Studies of Genomic Organization of the Ferrochelatase 
Gene Genomic representation of the ferrochelatase gene was ex-
amined by Southern blot hybridization. Restriction fragments from 
digestion of genomic DNA by EcoRI and PstI enzymes were hy-
bridized to a fu ll-length ferrochelatase cDNA probe. The pattern 
was identical in the patient, her parents, and the control (Fig 1). 
Ferrochelatase cDNA Studies PeR-based amplification of re-
verse-transcribed lymphocyte RNA demonstrated the presence of 
an abnormal ferrochelatase transcript in the patient and her father. 
These individuals possessed an additional 1.2-kb ferrochelatase 
transcript on amplification of cDNA obtained from mitogen-
stimulated lymphocytes (Fig 2). This species was not detected in 
amplified cDNA obtained from the mother or healthy controls. 
The additional cDNA product was also readi ly detected w hen tem-
plate obtained from freshly extracted mononuclear cells, rather than 
mitogen-stimulated cells, was amplified in the peR (data not 
shown) . Sequence analysis showed that all 10 clones of the short-
ened cDNA were found to lack a 120-bp region corresponding to 
exon 3 of the ferrochelatase gene. The loss of the exon ~equence in 
the shortened cD NA product was confirmed by demonstrating ab-
sence of an exon 3 AvaIl restriction site on di gestion of the amplified 
sequence by this endonuclease (AvaIl, New England Biolabs) (Fig 
3) . Sequence analysis of three of the original ten clones of the short-
ened eD NA species incidentally also demonstrated the use of an 
alternative exon 2 donor splice site 18 bp downstream from the 
usual site , a finding we had previously noted in two unrelated pa-
tients with proto porphyria (unpublished data) who were not found 
to have any abnormali ty of exon 3. Two independent clones con-
taining 1255 bp of ferrochelatase cDNA were obtained from the 
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Figure 1. Normal ferrochelatase gene restriction fragment pattern in the 
patient, as demonstrated by SOllthern blot analysis. Restriction digests of 
genomic DNA were hybridized to a full -length ferrochelatase eDNA probe. 
patient and analyzed . These corresponded to the normal human 
ferrochelatase sequence . 
In Fig 2 the misspliced cD NA species from the patient appears to 
be slightly more abundant than from her father. However, it is not 
possible to infer differences in the rates of ferrochelatase transcrip-
tion or steady-state levels of mRNA from these data because ampli-
fication of different templates is not directly proportional to their 
initial concentration in the peR. 
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Figure 2. An abnormal ferrochelatase eDNA in the patient and her father. 
The eDNA was obtained by reverse transcribing RNA extracted from mito-
gen-stimulated lymphocytes and amplified by the pe R. 
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Figure 3. Confirmation that the shortened ferrochelatase cDNA lacks 
exon 3. The first 600 bases of the cDNA were amplified by the peR. As 
expected. the normal 600-bp product was cut by the restriction enzyme 
AvaIl at a single site within exon 3 into a 180-bp fragment (not shown) as 
well as the 420-bp fragment. However, the shortened (480-bp) cDNA frag-
ment obtained from the patient and her father was resistant to cleavage. 
indicating loss of the unique restriction site on exon 3. 
Ferrochelatase Genomic Sequencing To investigate the ori-
gin of the variant ferrochelatase mRNA, we considered whether a 
mutation at an exon 3 splice site might be responsible for the splic-
ing defect in the patient and her father. Exon 3 and flanking regions 
of the ferrochelatase gene were amplified from genomic DNA tem-
plate obtained from the patient and her parents, and clones contain-
ing amplified products were isolated. Sequencing of the patient'S 
genomic ferrochelatase clones revealed a mutation at the exon 3 
donor splice site T(+2)~G (Fig 4) in 13 of21 clones. This trans-
version was identified in eight of 14 independent clones isolated 
from the patient'S father. All eight clones isolated from the patient's 
mother possessed only the wild-type sequence at the exon 3 donor 
site. All genomic clones isolated from the patient and her parents 
contained the normal sequence at the exon 3 acceptor site of the 
ferrochelatase gene. 
DISCUSSION 
In this pedigree we have shown that deficiency of heme synthase 
activity causing protoporphyria is associated with a point mutation 
(T-G) affecting a conserved nucleotide in the donor splice site of 
exon 3 of the human ferrochelatase gene (Fig 5). This transversion 
accounts for the defective processing of the primary RNA transcript 
revealed by molecular analysis of the cognate ferrochelatase cD N A. 
Sequence determination showed that the entire coding region 
corresponding to exon 3 of the gene was absent in the mRNA. 
Thus, the mutant allele would give rise to a polypeptide lacking 40 
amino acids, representing a deletion of more than 10% of the ma-
ture enzyme. 
Mutations such as the transversion described in this pedigree, 
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Figure 4. The exon 3 donor site mutation: sequence of cloned DNA ob-
tained from amplified fragments of the ferrochelatase gene. 
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Figure 5. Schematic representation of the exon 3 donor splice site muta-
tion. 
:vhich inv?lve cOllServed bases within donor splice sites, have been 
Identified I.n several human diseases. They cause aberrant splicing of 
the precedmg exon, which is thus excluded from the mature mRNA 
molec~le as has occurre~ l~ ere [13,22-24J. Following the loss of a 
recogmzable dO.nor Site, It IS lIkely that alternative splicing occurs as 
a result o~ recrUlt.ment .of the acceptor site of the following exon to 
take part 111 sphcmg With the preceding intact donor site [25]. 
,!"he propos ita and her father were heterozygous for the exon 3 
sphce-slte mutatIOn, and 111 both subjects this was accompanied by 
the appearance of t~e abnormal transcript. The patient had a pro-
found enzyme .de~clency (11.7% of mean control activity) and se-
vere. photose~sltlv.lty. However, her asymptomatic father was only 
pa.rtlally ~eficlent 111 ferrochelatase.( 48.3% of mean control ac tivity) 
With a shghtIy raised concentration of red-cell protoporphyrin. 
Thus inheritance of. this ~utation appears to be necessary for the 
development of ch11lcal dlsea~e, but may not be sufficient by itself. 
These r~sults cannot be explamed by a dominant-negative effect on 
heteroduller formation. Ferrochelatase exists as a functional dimer 
but if the product of the mutant allele interfered with catalyti~ 
activity by forming a heterodimer, then the same effect would be 
expected to occur in her father. A possible explanation for our find-
ings arises from the study of 91 families with protoporphyria by 
'Yen~ and Klasen [5J~ They showed parent-to-offspring transmis-
sIon m less than 10 Yo of cases. In most affected pedigrees one 
asymptomatic parent had fluorocytes whereas the other show~d no 
abnormality. These findings were taken to indicate that disease 
expression results from the inheritance of a gene defect from the 
biochemically abnormal,Parent and a second defect from the appar-
ently norm~l parent. Th.ls second defect was thought to occur with 
polymorphiC frequency m the population. We therefore consider it 
likely that an additional factor, inherited from the mother contrib-
utes to disease expression in our patient. It is notable that heme 
synthase activity in the mother was near the lower 95% confidence 
~imit of the range of reference (Table I), and was in fact lower than 
m any of the 36 healthy control subjects. However, our evidence 
suggests that the putative maternal defect is unlikely to lie in the 
ferrochelatase gen~ itself; no abnormal restriction fragments were 
detected on genomic Southern blotting with a ferrochelatase cDNA 
probe and the sequence of the patient'S full-length cDNA deter-
mined in all but 20 bp, was also normal. ' 
Other studies based on the analysis of ferrochelatase cDNA have 
also failed to resolve difficulties in establishing the mode of inheri-
tance of symptomatic protoporphyria. For example, N akahashi el al 
have reported a severely affected patient who was heterozygous for 
a ferrochelatase exon 9 donor site mutation, as were four asympto-
matic. relati:ves of t~le index caseJ13]. In further work we propose to 
~xamlI1e ellIS questIOn by analyzlllg the segregation of disease alleles 
111 affected families using an informative and tightly linked poly-
morphic dinucleotide repeat sequence that we have recently re-
po;ted in intron 2 of the ferrochelatase gene [26]. Clearly, however, 
It IS pOSSIble that other heritable factors or even environmental 
influences might also contribute to the functiona.l effects of partial 
ferrochelatase deficiency and thus affect disease expression. 
We note that the genomic mutations reported by other investiga-
tors in association with putative splicing defects involving exons 2 
[12] and 10 [14] do not involve bases within the consensus sequence 
of the highly conserved splice sites. For this reason we are unclear as 
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to the causal significance of these base substitutions. Most studies 
reported so far have analyzed ferrochelatase cDNA obtained from 
lymphocytes transformed using Epstein-Barr virus or a mitogen. 
We have detected minor transcripts representing alternative splic-
ing of exon 2 resulting .from activation of a down~tream cryptic 
donor site in mitogen-stimulated lymphocytes obtamed from our 
patient and two u~rel~ted individuals .. It remains possible ~hat the 
transcriptional activation accompanymg transformation m lym-
phocytes may artefactually in.crease the al?pearance of minor tran-
scripts not related to the pnmary genetic defect responsible for 
proto porphyria. We therefore believe that car.eful examination. of 
genomic as well as cDNA sequences IS reqUIred before putative 
splice site mutations are unequivocally accepted. Finally, it is note-
worthy that we have found that the base guanine was present at 
cDNA position 287 in all our clones, resulting in an arginine at 
amino acid 96 in agreement with Lamoril et af [7), rather than the 
adenine in a glutamine codon at this position that had been previ-
ously reported [9]. 
In summary, we report a hitherto unrecognized mutation in the 
ferrochelatase gene that results in aberrant RNA splicing and the 
enzyme deficiency associated with erythropoietic protoporphyria. 
The presence of the mutation appears to be necessary for the devel-
opment of biochemical abnormalities but does not allow sympto-
matic disease to be predicted with certainty. Further molecular 
characterization of ferrochelatase genes from other patients with 
this disorder are underway to determine the diagnostic utility and 
importance of the present findings, and will form the basis of studies 
to clarify the unusual inheritance of this disease. 
We thallk Dr.]. Fergllso'l of the Photobiology U'lit, Nitlewells Hospital, Dlllldee for 
riferrillg tltis patient alld the Wellcome Trllstfor sllpport. Mr. Philip Ball gave expert 
assistallce witlt the artwork alld Mrs.Joan Grantham killdly rendered die ma'lUscript 
suitable for pl~blication. 
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